Jason Rhodes
InvestorPartner at Atlas Venture
Cambridge, Massachusetts, United States
Writes $500K – $5M checks · typically $2M
About
Jason Rhodes is a partner at Atlas Venture focused on creating and building therapeutics companies. He was the founding CEO of Dyne Therapeutics and Rectify Pharmaceuticals and founding CEO of Disarm Therapeutics (acquired by Eli Lilly), and previously held leadership roles at Alnylam Pharmaceuticals and Epizyme. Earlier he was a founder and partner at Fidelity Biosciences (now F-Prime Capital), where he led therapeutics investments. He holds a BA from Yale University and an MBA from the Wharton School.
Invests in
Biotech
Experience
- American Academy in RomeTrusteecurrent2026 — present
- Atlas VenturePartnercurrent2014 — presentCambridge, MA
- Rectify PharmaExecutive Chair (and founding CEO)current2020 — present
- Dyne TherapeuticsChairman (and founding CEO)current2017 — presentCambridge, MA
- Berklee College of MusicPresidential Advisory Council, Member2009 — 2022
- Disarm Therapeutics (acquired by Lilly in 2020)Chairman (and founding CEO)2016 — 2020
- EpizymePresident and CFO2010 — 2014NASDAQ: EPZM www.epizyme.com
- AlnylamVice President, Business Development2007 — 2010
- Fidelity Biosciences(F-Prime)Partner2001 — 2007
Education
- Yale UniversityBA, History - modern diplomatic and financial history
- The Wharton SchoolMBA
Skills & more
+12 more
OncologyMergersPrivate EquityDrug DiscoveryLifesciencesTechnology TransferPharmaceutical IndustryCommercializationBusiness DevelopmentStrategic AlliancesProduct DevelopmentProduct ManagementFrom Jason's professional profile.
Same school
Also attended Yale University493
+ 487 more
Also attended The Wharton School1,323
+ 1,317 more
Shared employers
Also worked at Rectify Pharma4
Also worked at Dyne Therapeutics5
Also worked at Berklee College of Music6
Investments
Led
FoldRx
Board seats
AAVantgarde BioAccent TherapeuticsDisarm TherapeuticsDyne TherapeuticsK36 TherapeuticsKaryoVerseMithrilRectify PharmaceuticalsWeaver
Per the firm's website.
Colleagues at Atlas Venture
Network5
Investors connected to Jason in public investor directories — a warm-intro map.








.jpeg)


























